Annexon Biosciences
Annexon Biosciences is a biopharmaceutical company focused on developing therapies for neuroinflammatory diseases, with a pipeline targeting autoimmune, neurodegenerative and ophthalmic conditions. They are seeking talented individuals to join their innovative team and contribute to clinical trial development and management.
Headquarters
South San Francisco, California, United States
Company Size
51-200 employees
Founded
2011
Annexon Biosciences is a biopharmaceutical company developing next‑generation complement therapies by targeting C1q, the initiating molecule of the classical complement pathway. By blocking C1q, Annexon aims to prevent downstream immune‑mediated damage in autoimmune, neurodegenerative (including Alzheimer’s and Huntington’s) and ophthalmic diseases affecting the body, brain, and eye. The company advances C1q‑targeted biologics through a pipeline of therapeutic candidates intended to provide disease‑modifying treatments for conditions driven by classical complement activation.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Annexon Biosciences.
Annexon Biosciences stock rating reiterated by Cantor Fitzgerald
Jan 14, 2026
Medical Director, Clinical Development, Neurology
Zenas BioPharma
Senior Director, Clinical Operations
Jade Biosciences
Clinical Trial Manager (CTM) Contract
Jasper Therapeutics
Senior Director of Clinical Development for Rheumatology
Spyre Therapeutics
Clinical Trial Manager (CTM)
Caribou Biosciences, Inc.
Director, Clinical Development
Neurocrine Biosciences